Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, forecasts that the Parkinson's disease drug market will double by 2011. According to a new Pharmacor report entitled Parkinson's Disease, a growing population of people diagnosed with the disease and the increased use of combination therapies to treat the illness will be significant factors in the growth of the market.
"Widespread use of dopamine agonists and other novel agents (dopaminergic and nondopaminergic)--both as adjuncts to levodopa and as early treatment to delay levodopa use --will significantly boost the value of the overall drug market for Parkinson's disease," said Tricia Nagle, analyst at Decision Resources. "For 2011, we estimate that major-market sales of drugs to treat Parkinson's disease will exceed $2.5 billion, more than doubling 2001 sales."
Disease Background-Parkinson's Disease
Parkinson's disease is a chronic, progressive, neurodegenerative disorder characterized by a loss of dopaminergic neurons in the substantial nigra and degeneration of afferent dopaminergic fibers. Levodopa, or L-dopa, remains the most potent medication available for treating this disorder, and it is eventually prescribed to the majority of Parkinson's disease patients.
In 2001, more than 2.7 million people had Parkinson's disease (including diagnosed and undiagnosed cases) in the seven major pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom and Japan). In the same year, prescription drugs to treat Parkinson's disease generated just over $1.2 billion in sales.
About Pharmacor from Decision Resources
Pharmacor is a unique family of studies based on primary and secondary research conducted by Decision Resources' on-staff experts. Each comprehensive study assesses a host of market-impacting factors and analyzes the commercial outlook for drugs in research and development. Cardium, Cognos, Immune and Inflammatory Disorders, Infectious Disease, Metabolic Disorders, Psychiatric Disorders, and Onkos concentrate on specific therapeutic areas. Mosaic covers high-interest disease states. Parkinson's Disease is a Cognos report.
About Decision Resources
Decision Resources, Inc., is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The company has provided strategic information services for 30 years, assessing international pharmaceutical and health care industry trends. Visit Decision Resources at www.decisionresources.com.
All company brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Elizabeth Marshall Decision Resources, Inc. 781-296-2563 email@example.com
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION
AP Archive: http://photoarchive.ap.org/
PRN Photo Desk, 888-776-6555 or 212-782-2840
SOURCE: Decision Resources, Inc.
CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-
Web site: http://www.dresources.com/